Introduction
============

Prostate cancer (PC) is the most common malignancy among males,[@b1-ott-6-725] and accounts for 28% of incident cancer cases in men. In 2012, there were an estimated 241,740 new cases of PC, along with approximately 28,170 PC-induced deaths in the US.[@b2-ott-6-725] Based on data between 1999 and 2005, approximately 80% of these new cases of PC were diagnosed at localized stages,[@b3-ott-6-725] with a 5-year PC-specific survival rate approaching 100%. Common treatments include radical prostatectomy (RP), active surveillance, radiation, and androgen-deprivation treatment (ADT). The National Comprehensive Cancer Network guidelines and European Association of Urology guidelines for management among clinically localized PC patients recommend all of these treatments except ADT as monotherapy.[@b4-ott-6-725],[@b5-ott-6-725]

PC is a hormonally sensitive tumor, which usually responds to pharmacological manipulation of the androgen receptor. ADT serves as an important adjuvant strategy for the treatment of advanced PC,[@b6-ott-6-725]--[@b9-ott-6-725] particularly for patients primarily treated with radiotherapy. However, no randomized controlled trials (RCTs) have evaluated ADT as monotherapy among clinically localized PC patients. Furthermore, large population-based studies observed inferior PC-specific survival and nonincreased overall survival following primary ADT (PADT) when compared to watchful waiting.[@b10-ott-6-725],[@b11-ott-6-725] Despite the lack of evidence of clinical benefits and recommendations, PADT has been commonly used among clinically localized patients. According to the Cancer of the Prostate Strategic Urologic Research Endeavor (CAPSURE) study, 14.4% of clinically localized patients received PADT between 1990 and 2008.[@b12-ott-6-725]

On the other hand, RP is a commonly recommended and used treatment for clinically localized PC patients, especially for those with a life expectancy of 10 years or more. Approximately 60,000 RP procedures are performed annually in the US.[@b13-ott-6-725] Its clinical benefit among early stage non-prostate-specific antigen (PSA)-detected PC patients has been demonstrated in the Scandinavian Prostate Cancer Group study 4 (SPCG-4).[@b14-ott-6-725] The most recent results in a predominantly PSA-detected population found a nonsignificant reduction in mortality from radical prostatectomy compared to conservative management.[@b15-ott-6-725] The optimal treatment for clinically localized PC is anything but clear.

To the best of our knowledge, there is no ongoing RCT to compare PADT to RP. Our previous retrospective analysis of the overall survival rates among veterans found that PADT was associated with threefold-higher overall mortality rate when compared to RP among localized PC patients.[@b16-ott-6-725] However, without important survival predictors, eg, the Gleason score, the findings in the Veterans Affairs study were not conclusive.

Knowledge of direct comparison between PADT and RP in terms of survival outcome is lacking in the literature and absolutely needed by patients and physicians. This study aimed to provide this kind of information to help these patients and their physicians to understand these two therapies better and thus to choose the appropriate one. We hypothesized that PADT was associated with higher PC-specific mortality and overall mortality.

Methods
=======

Data source
-----------

The Surveillance, Epidemiology, and End Results (SEER)-Medicare dataset 1998--2007 was used in this study. The SEER program, funded by the National Cancer Institute, is an authoritative source of information on cancer incidence and survival in the US. SEER's 17 registries currently cover approximately 28% of the US population. This study was approved by the Tulane University Institutional Review Board. Informed consent was waived by the board, because the data did not contain personal identifiers.

Study design
------------

The patients in the study needed to have at least have one diagnosis for PC (International Classification of Diseases \[ICD\]-9 diagnosis 185.xx). Other inclusion criteria were: (1) PC at the clinically localized stage (T1--T2, N0, M0); (2) no documented cancer diagnosis before PC diagnosis; (3) age 66--74 years in the year of diagnosis; (4) to at least have Medicare insurance coverage (parts A and B) 1 year before the time of the first diagnosis of PC, to ensure that 1-year baseline information was available; and (5) either ADT or RP as monotherapy initiated within 180 days after the first diagnosis of PC.

The treatment initiation date was used as the index date. The individuals were followed from the index date until death, the end of data availability (December 31, 2007), or dropout from Medicare, whichever happened first. The year before the index-date data from Medicare was used to examine the baseline characteristics.

Treatment definitions
---------------------

A categorical variable for therapies that consisted of mutually exclusive categories for the therapy received (RP surgery alone, ADT alone, conservative management, or others) were created using information from corresponding variables in the SEER-Medicare data set.

ADT was identified using a reported algorithm,[@b17-ott-6-725] including the Healthcare Common Procedure Coding System (HCPCS) codes for orchiectomy: 54520, 54521, 54522, 54530, 54535, or the ICD-9-CM code 62.4, and the HCPCS codes for luteinizing hormone-releasing hormone agonists: J1950, J9202, J9218, or J9219. RPs were identified using the HCPCS codes 55821, 55801, 55810, 55812, 55815, 55831, 55840, 55842, 55845, or ICD-9-CM codes 60.3, 60.4, 60.5, 60.6, and 60.62.[@b18-ott-6-725]

Data analysis
-------------

The propensity score was assessed from the logistic model estimating the probability of receiving PADT versus RP for each patient. A PADT recipient was then matched to an RP recipient when their predicted probabilities were the closest, with a maximum distance tolerance of 0.005 in the propensity score.[@b19-ott-6-725] Propensity score-matching was expected to adjust for treatment-selection bias, which is a common bias in observational studies due to the lack of randomization.[@b19-ott-6-725] The covariates used for the propensity-matching analysis included patient characteristics (race, marital status, urban residence, regions), cancer status (PSA, T-score, Gleason score risk groups, diagnosis year), coexisting disease (Charlson comorbidity index \[CCI\], hypertension, diabetes), and healthcare utilization (hospitalization, surgery). We included these variables because we observed significant differences in these variables between these two cohorts, indicating these variables may impact treatment choice. PSA ≤ 10 ng/mL corresponds to low risk, PSA 11--20 ng/mL to median risk, and PSA \> 20 ng/mL to high risk.[@b20-ott-6-725]

After the matching, two cohorts with comparable baseline information were expected. Chi-squared tests for categorical variables and *t*-tests for continuous variables were used to verify if all the baseline characteristics were comparable. Overall survival rate was analyzed using the Kaplan--Meier method, and the hazard ratio (HR) was estimated using Cox proportional hazards (PH) regression between propensity score-matched cohorts. The Fine and Gray competing risk model was used to model PC-specific survival. This method showed better performance than the standard Cox PH model when modeling competing risk survival among the elderly population.[@b21-ott-6-725]

Results
=======

Before propensity score-matching, there were 5804 patients in the PADT group and 5182 patients in the RP group. The baseline differences between these two groups were significant ([Table 1](#t1-ott-6-725){ref-type="table"}). Patients in the RP cohort were more likely to be white, married, with a better Gleason score, and with a better overall health status (lower CCI, and fewer healthcare utilizations).

After propensity score-matching, there were 1624 in the PADT cohort and 1624 in the RP cohort. The average age in the PADT cohort was 70.25 (standard deviation 2.50) years, and was 70.21 (standard deviation 2.47) years in the RP cohort (*P* = 0.67). In [Table 2](#t2-ott-6-725){ref-type="table"}, all the baseline information was comparable (all *P*-values \>0.35). In this matched sample, the majority were white, accounting for 81.59% in the PADT group and 81.77% in the RP cohort. The overall health status based on CCI and health-care utilizations was also comparable. The two groups had exactly the same number of patients in each index year and also at each PSA level. About 78.88% of PADT receipts were diagnosed at the T2 stage and 79.00% of RP receipts diagnosed at the T2 stage. In each group, about 50% of the patients had moderate/well-differentiated (Gleason score 2--7) PC and 50% with poorly differentiated (Gleason score 8--10) cancer.[@b10-ott-6-725]

The median follow up was 2.87 years in the PADT group and 2.95 years in the RP group. There were a total of 266 deaths (16.38%) in the PADT cohort and 56 (3.45%) in the RP cohort ([Figure 1](#f1-ott-6-725){ref-type="fig"}, Kaplan--Meier curve, *P* \< 0.05). According to Kaplan--Meier estimates, the 3-year, 5-year, and 8-year survival rate was 89.66%, 74.81%, and 43.39% in the PADT cohort, respectively, and 96.06%, 92.08%, 79.62% in the RP cohort, respectively. In the Cox PH regression model ([Table 3](#t3-ott-6-725){ref-type="table"}), PADT was associated with an increased risk of overall mortality (HR = 2.98, 95% confidence interval \[CI\] 2.35--3.79; *P* \< 0.001).

Also in this Cox PH model, married patients were less likely to die (HR = 0.77, 95% CI 0.61--0.97; *P* = 0.026) than the unmarried patients. When compared to patients with a CCI score of zero, the patients with more comorbidities were more likely to die (HR = 1.66, 95% CI 1.27--2.17; *P* \< 0.001 for patients in the CCI ≤ 2 group; and HR = 2.21, 95% CI 1.51--3.22; *P* \< 0.001 for patients in the CCI \> 2 group). Patients who had been previously hospitalized were also more likely to die (HR = 1.81, 95% CI 1.17--2.80; *P* = 0.007).

There were 60 (3.69%) PC-specific deaths in the PADT cohort and four (0.25%) PC-specific deaths in the RP cohort. According to the Fine and Gray competing risk model ([Figure 2](#f2-ott-6-725){ref-type="fig"} and [Table 4](#t4-ott-6-725){ref-type="table"}), PADT was associated with increased risk of PC-specific mortality (HR = 12.47, 95% CI 4.48--34.70; *P* \< 0.001).

Meanwhile, a worse Gleason score was associated with a higher likelihood of dying of PC (HR = 3.16, 95% CI 1.77--5.64; *P* \< 0.001). Other independent variables were not significant after propensity score-matching (all *P*-values \>0.05).

Discussion
==========

This study documented the survival comparison between PADT and RP as monotherapy among clinically localized PC patients in terms of PC-specific mortality and overall mortality. One of the strengths of this study was that propensity score-matching was employed to ensure the cohorts had comparable baseline information. These baseline variables included the most important survival predictors, eg, the Gleason score groups, PSA, age, CCI, and the index year of treatment initiation. This strategy is powerful enough to adjust for observable selection bias, and has been commonly used to better draw causal inference from observational studies.

This study found that PADT was associated with a 12-fold higher PC-specific mortality rate than RP after controlling for the important survival predictors. Because PC-specific mortality was a primary outcome in many PC clinical trials, this comparison between PADT and RP in terms of PC-specific mortality from this study can be related to the outcomes from clinical trials and also from real-world observational studies. So far, there is no evidence of any clinical benefits of PADT for localized PC patients in the literature. On the other hand, treatment with RP was associated with a significantly lower risk of disease-specific mortality and overall mortality according to the SPCG-4.[@b22-ott-6-725] Meanwhile RP has provided good long-term clinical outcomes for patients with high-risk localized PC and avoided the use of ADT in approximately 70% of these patients.[@b23-ott-6-725] RP (with adjuvant hormonal therapy) provided improved local control in patients with lymph node-positive PC.[@b24-ott-6-725] However, the Prostate Cancer Intervention Versus Observation Trial found that when compared to observation, RP produced reductions in all-cause and PC mortality rates, but the difference was not significant except in certain subsets, and less than 3% in absolute terms over 12 years.[@b15-ott-6-725] It is still premature to label RP as the gold standard for clinically localized PC, but RP displayed obvious dominance over ADT as a monotherapy among these patients in this study.

Patients with a worse Gleason score had an increased PC-specific mortality in this study. This finding was not a surprise. In the literature, a Gleason score of 7 or greater indicated the probability of a 29% chance of dying of PC, and the corresponding value for a Gleason score of 8 or greater was 48%, based on a 20-year follow-up of a population-based non-PSA detected cohort in Sweden.[@b25-ott-6-725] This makes the Gleason score one of the most important survival predictors among PC patients.

Also, PADT was associated with a threefold-higher risk of overall mortality. This is confirmation of our earlier finding that PADT was associated with a threefold increase in overall mortality rate after a median follow up of 4.3 years when compared to RP.[@b16-ott-6-725] Although propensity score-matching was also employed to make sure that the baseline characteristics were comparable in the VA study, the Gleason score was not available. The Gleason score risk group was available in the SEER-Medicare data. One possible reason for the increased overall mortality rate associated with PADT is that ADT for PC could induce metabolic syndrome, which may contribute to noncancer-related (predominantly cardiovascular) morbidity and mortality.[@b26-ott-6-725]

In this matched sample, patients with more comorbidities (CCI) had an increased overall mortality rate. Previous findings revealed that CCI was a strong predictor of survival among localized PC patients.[@b27-ott-6-725] It is known that the majority of PC patients die with PC rather than of PC. This has been confirmed in this study, where the likelihood of death from competing causes exceeded the risk of death from PC. This makes comorbidity management for PC extremely important. Also, married patients had reduced overall mortality. Married patients were more likely to get family support and better family care. This could be the reason married people survived longer in this study. Lastly, people with a previous use of hospitalization were more likely to die. Previous hospitalization was an indicator of worse overall health status, which might result in shorter survival.

This was an observational study rather than an RCT. First, although propensity score-matching was employed to balance the baseline characteristics, selection bias may still be an issue due to unobserved variables, eg, patient's income information and provider's characteristics. However, the most important survival predictors in the literature, eg, the Gleason score risk group, PSA, CCI, and age, were comparable after matching. Second, this study merely focused on survival outcomes and did not assess the side effects and quality of life between these two cohorts. Third, people in this study were aged 66 years or older. This was a highly selective population, and could be one of the reasons we observed different survival results from what has been reported in PIVOT study.[@b13-ott-6-725] Caution should be exercised in generalizing findings from this study to other populations. Despite these limitations, this was the first study that aimed to explore the comparison in terms of PC-specific mortality and overall mortality between PADT and RP among localized PC patients. Its findings have significant clinical implications and contribute to the literature on survival comparison among treatment options for localized PC patients. The highly selective population could also be one of the reasons we observed different treatment patterns among these patients when compared to patients in the CAPSURE registry.[@b12-ott-6-725] Caution should be exercised in generalizing findings from this study to other populations.

In summary, PADT was associated with increased overall mortality and PC-specific mortality when compared to RP. The difference in PC-specific mortality is mostly attributable to the depression of cancer progress associated with RP, while the difference in overall survival is likely due to increased metabolic syndrome associated with PADT. All these findings support the conclusion that ADT as a monotherapy may not be an appropriate therapeutic choice for the clinically localized PC population. Patients should be well informed by their doctors about this before they make treatment selections together.
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###### 

Baseline information between the PADT and RP cohorts before propensity score-matching

                               PADT   RP      *P*            
  ---------------------------- ------ ------- ------ ------- ----------
  Race                                                       \<0.0001
   Not white                   1357   23.38   741    14.30   
   White                       4447   76.62   4441   85.70   
  Married                                                    \<0.0001
   No                          2064   35.56   896    17.29   
   Yes                         3740   64.44   4286   82.71   
  Urban residence                                            \<0.0001
   No                          708    12.20   480    9.26    
   Yes                         5096   87.80   4702   90.74   
  PSA                                                        \<0.0001
   Low                         583    10.04   116    2.24    
   Median                      2447   42.16   2378   45.89   
   High                        1003   17.28   791    15.26   
   Positive                    48     0.83    151    2.91    
   Unknown                     973    16.76   1423   27.46   
  T-score                                                    \<0.0001
   T1                          3318   57.17   768    14.82   
   T2                          2486   42.83   4414   85.18   
  Gleason score risk group                                   \<0.0001
   Moderately differentiated   2719   46.85   3193   61.62   
   Poorly differentiated       3085   53.15   1989   38.38   
  Year at diagnosis                                          \<0.0001
   1998                        95     1.64    217    4.19    
   1999                        95     1.64    202    3.90    
   2000                        226    3.89    348    6.72    
   2001                        223    3.84    424    8.18    
   2002                        264    4.55    429    8.28    
   2003                        437    7.53    330    6.37    
   2004                        1352   23.29   1006   19.41   
   2005                        1118   19.26   821    15.84   
   2006                        1153   19.87   708    13.66   
   2007                        841    14.49   697    13.45   
  Region                                                     \<0.0001
   North-central               794    13.68   756    14.59   
   Northeast                   1710   29.46   613    11.83   
   South                       1336   23.02   919    17.73   
   West                        1964   33.84   2894   55.85   
  CCI group                                                  \<0.0001
   0                           2329   40.13   3064   59.13   
   ≤2                          2264   39.01   1693   32.67   
   \>2                         1211   20.86   425    8.20    
  Hypertension                                               \<0.0001
   No                          1057   18.21   1400   27.02   
   Yes                         4747   81.79   3782   72.98   
  Diabetes                                                   \<0.0001
   No                          3474   59.86   3787   73.08   
   Yes                         2330   40.14   1395   26.92   
  Hospitalization                                            \<0.0001
   No                          4758   81.98   4715   90.99   
   Yes                         1046   18.02   467    9.01    
  Outpatient visit                                           0.9922
   No                          1581   27.24   1412   27.25   
   Yes                         4223   72.76   3770   72.75   
  Surgery                                                    \<0.0001
   No                          5046   86.94   4842   93.44   
   Yes                         758    13.06   340    6.56    

**Abbreviations:** PADT, primary androgen-deprivation treatment; RP, radical prostatectomy; PSA, prostate-specific antigen; CCI, Charlson comorbidity index.

###### 

Baseline information between PADT and RP cohorts after propensity score-matching

                                    PADT   RP      *P*            
  --------------------------------- ------ ------- ------ ------- --------
  Race                                                            0.8898
   Not white                        299    18.41   296    18.23   
   White                            1325   81.59   1328   81.77   
  Married                                                         0.3691
   No                               396    24.38   418    25.74   
   Yes                              1228   75.62   1206   74.26   
  Urban residence                                                 0.3640
   No                               199    12.25   184    11.33   
   Yes                              1425   87.75   1440   88.67   
  PSA                                                             1.000
   Low                              841    51.79   841    51.79   
   Median                           126    7.76    126    7.76    
   High                             53     3.26    53     3.26    
   Positive                         372    22.91   372    22.91   
   Unknown                          232    14.29   232    14.29   
  T-score                                                         0.9306
   T1                               343    21.12   341    21.00   
   T2                               1281   78.88   1283   79.00   
  Gleason score risk group                                        0.6740
   Moderately/well differentiated   814    50.12   826    50.86   
   Poorly differentiated            810    49.88   798    49.14   
  Year at diagnosis                                               1.000
   1998                             26     1.60    26     1.60    
   1999                             30     1.85    30     1.85    
   2000                             85     5.23    85     5.23    
   2001                             89     5.48    89     5.48    
   2002                             97     5.97    97     5.97    
   2003                             114    7.02    114    7.02    
   2004                             369    22.72   369    22.72   
   2005                             323    19.89   323    19.89   
   2006                             279    17.18   279    17.18   
   2007                             212    13.05   212    13.05   
  Region                                                          0.9202
   North-central                    247    15.21   235    14.47   
   Northeast                        287    17.67   283    17.43   
   South                            333    20.50   333    20.50   
   West                             757    46.61   773    47.60   
  CCI group                                                       0.5710
   0                                833    51.29   803    49.45   
   ≤2                               609    37.50   634    39.04   
   \>2                              182    11.21   187    11.51   
  Hypertension                                                    0.4510
   No                               390    24.01   383    23.58   
   Yes                              1234   75.99   1241   76.42   
  Diabetes                                                        0.7726
   No                               1113   68.53   1093   67.30   
   Yes                              511    31.47   531    32.70   
  Hospitalization                                                 0.5831
   No                               1444   88.92   1434   88.30   
   Yes                              180    11.08   190    11.70   
  Outpatient use                                                  0.5171
   No                               436    26.85   452    27.83   
   Yes                              1188   73.15   1172   72.17   
  Surgery                                                         0.9491
   No                               1496   92.12   1497   92.18   
   Yes                              128    7.88    127    7.82    

**Abbreviations:** PADT, primary androgen-deprivation treatment; RP, radical prostatectomy; PSA, prostate-specific antigen; CCI, Charlson comorbidity index.

###### 

Cox proportional hazards regression on overall survival between the PADT and RP cohorts after propensity score-matching

                          HR     Lower 95% CI   Higher 95% CI   *P*
  ----------------------- ------ -------------- --------------- ---------
  PADT                    2.98   2.35           3.79            \<0.001
  Age at diagnosis        1.03   0.99           1.08            0.154
  White                   0.80   0.62           1.02            0.073
  Married                 0.77   0.61           0.97            0.026
  Urban                   0.74   0.54           1.02            0.065
  Region                                                        
   Northeast              1.14   0.75           1.74            0.548
   South                  1.19   0.82           1.71            0.359
   West                   1.17   0.84           1.63            0.354
  PSA                                                           
   Low                    0.76   0.43           1.33            0.339
   Median                 1.20   0.61           2.36            0.606
   High                   1.30   0.59           2.86            0.516
   Unknown                1.30   0.89           1.89            0.179
  T2                      1.33   1.00           1.76            0.046
  Worse Gleason score     1.29   1.02           1.62            0.032
  CCI                                                           
   ≤2                     1.66   1.27           2.17            \<0.001
   \>2                    2.21   1.51           3.22            \<0.001
  Diabetes (yes)          0.98   0.76           1.26            0.886
  CVD history             1.14   0.98           1.31            0.088
  Year at diagnosis                                             
   1998                   0.01   0.01           0.03            \<0.001
   1999                   0.03   0.01           0.09            \<0.001
   2000                   0.03   0.01           0.08            \<0.001
   2001                   0.07   0.03           0.17            \<0.001
   2002                   0.09   0.04           0.22            \<0.001
   2003                   0.11   0.05           0.27            \<0.001
   2004                   0.08   0.04           0.17            \<0.001
   2005                   0.16   0.08           0.32            \<0.001
   2006                   0.30   0.15           0.59            0.001
  Hospitalization (yes)   1.81   1.17           2.80            0.007
  Surgery (yes)           0.86   0.53           1.39            0.531
  Outpatient use (yes)    1.18   0.90           1.54            0.223
  Hypertension (yes)      1.12   0.85           1.48            0.420

**Abbreviations:** PADT, primary androgen-deprivation treatment; RP, radical prostatectomy; HR, hazard ratio; CI, confidence interval; PSA, prostate-specific antigen; CCI, Charlson comorbidity index; CVD, cardiovascular disease.

###### 

Competing risk analysis of prostate cancer-specific survival between the PADT and RP cohorts after propensity score-matching

                          HR      Lower 95% CI   Higher 95% CI   *P*
  ----------------------- ------- -------------- --------------- ---------
  PADT                    12.47   4.48           34.7            \<0.001
  Age at diagnosis        0.96    0.86           1.07            0.45
  White                   0.94    0.49           1.82            0.86
  Married                 0.86    0.48           1.51            0.59
  Region                                                         
   Northeast              1.59    0.58           4.38            0.37
   South                  1.08    0.43           2.71            0.86
   West                   1.27    0.58           2.76            0.55
   Urban                  0.53    0.28           1.00            0.05
  PSA                                                            
   Positive               2.68    0.58           12.27           0.21
   Median                 2.43    0.71           8.38            0.16
   High                   1.23    0.15           9.96            0.84
   Unknown                2.43    0.79           7.49            0.12
  T2                      1.71    0.86           3.42            0.13
  Worse Gleason score     3.16    1.77           5.64            \<0.001
  Year at diagnosis                                              
   1998                   0.40    0.04           4.47            0.46
   1999                   0.45    0.05           4.50            0.50
   2000                   0.43    0.05           3.68            0.45
   2001                   0.40    0.04           3.65            0.41
   2002                   0.67    0.08           5.27            0.70
   2003                   0.29    0.03           2.46            0.25
   2004                   0.24    0.05           1.13            0.07
   2005                   0.31    0.06           1.58            0.16
   2006                   0.37    0.06           2.45            0.31
  CCI ≤ 2                 0.82    0.40           1.68            0.59
  CCI \> 2                1.12    0.35           3.65            0.85
  Hospitalization (yes)   1.89    0.80           4.46            0.14
  Surgery (yes)           1.02    0.33           3.15            0.97
  Outpatient use (yes)    1.58    0.81           3.07            0.18
  Hypertension (yes)      1.01    0.55           1.83            0.98
  Diabetes (yes)          0.96    0.46           2.02            0.92
  CVD history             0.86    0.55           1.34            0.49

**Abbreviations:** PADT, primary androgen-deprivation treatment; RP, radical prostatectomy; HR, hazard ratio; CI, confidence interval; PSA, prostate-specific antigen; CCI, Charlson comorbidity index; CVD, cardiovascular disease.
